However, certain types of cancer, like MYC-driven prostate cancer, are refractive to PI3K-AKT-mTORC inhibitors, but treatment with CX-5461 in combination with an inhibitor of PIM kinase, frequently upregulated in these cancers, showed improved therapeutic efficiency [88]. Here, MYC is linked to cancer.